

# Is your lab overcalling *C. difficile* positive results?

ImmunoCard® Toxins A&B is a rapid, easy-to-use EIA test that helps correctly identify active *C. difficile* infections from carriers by detecting the presence of fecal toxins in stool.

55.3% of patients with a positive *C. difficile* PCR test are negative for toxin production and have outcomes comparable to patients with no *C. difficile* detected.<sup>1</sup>

- The rate of healthcare-associated CDI (*C. difficile* infection) has been increasing, and the diagnosis of CDI is estimated to raise the cost of a hospitalization stay by 51% in the United States<sup>2</sup>
- C. difficile associated diarrhea increases hospital costs by 40% per case<sup>3</sup>
- The US burden of CDI is close to 500,000 infections annually<sup>4</sup>

#### Is your lab currently testing for C. difficile with the most accurate test?

- · What impact have the new quidelines and algorithm discussions had on your lab?
- How are the current reporting requirements of hospital-acquired infections impacting your lab and the health system?





#### Implement Algorithm Guidelines

The 2018 IDSA/SHEA Guidelines of C. difficile
Infection recommend toxin testing be used as
part of an algorithm to confirm the presence of
active toxin production.<sup>4</sup>

#### **Identify True Positives**

- Use this test in combination with a molecular method to correctly identify patients with active toxin infection versus C. difficile carriers.
- Adding tests, such as a toxin card, increases the positive predictive value (PPV) of C. difficile testing.<sup>4</sup>

#### **Superior Performance**

	Sensitivity	Specificity	PPV	NPV
Meridian ImmunoCard® Toxins A&B <sup>5</sup>	93.1%	98.9%	97.1%	97.2%
TECHLAB Quik Chek Complete <sup>6</sup>	87.8%	99.4%	95.8%	98.1%
Remel Xpect C. difficile Toxin A/B <sup>7</sup>	86.3%	96.2%	84.1%	96.8%



### **Product Specifications**

ImmunoCard® Toxins A&B is a rapid, qualitative, horizontal-flow enzyme immunoassay (EIA) for detecting *Clostridium difficile* Toxins A and B in human stool.

#### **Turnaround Time**

15 minutes

#### **Shelf Life**

12 months

#### Sample Type

Stool

#### Sample Storage

Store at 2-8C for up to 4 days

Store frozen ( $\leq$  -20C) until tested, with up to 3 freeze/thaw cycles

#### Kit Storage

Kit and all reagents should be stored at 2-8C

#### Performance

(compared to Cytotoxin)

Sensitivity

98.9%

Specificity

**Catalog Number** 

**CPT Codes** 

ImmunoCard® Toxins A&B — 712050

87324

#### References

- Polage, Christopher, et al. "Overdiagnosis of Clostridium difficile Infection in the Molecular Test Era." JAMA Intern Med. 2015 Nov;175(11):1792-801. doi: 10.1001/jamainternmed.2015.4114
- Zhang, Dongmu et al. "Attributable Healthcare Resource Utilization and Costs for Patients with Primary and Recurrent Clostridium difficile Infection in the United States." Clinical infectious diseases: an official publication of the Infectious Diseases Society of America vol. 66,9 (2018): 1326-1332. doi:10.1093/cid/cix1021
- HealthLeaders. C. diff Infection Raises Hospital Costs by 40% per Case. Retrieved from https://www.healthleadersmedia.com/clinical-care/c-diff-infection-raises-hospital-costs-40-case
- L Clifford McDonald, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA), Clinical Infectious Diseases, Vol 66, 7 (March 2018): e1e48. https://doi.org/10.1093/cid/cix1085
- 5. ImmunoCard Toxin A&B Package Insert. Rev 12/2016
- 6. C. DIFF QUIK CHEK COMPLETE Package Insert. Rev 06/18
- 7. Remel X/pect Clostridium difficile Toxin A/B Package Insert. Rev 4/2012

## Ready to get a handle on testing for *C. difficile*? Let's talk.

Contact a specialist at 1-888-763-6769.

meridianbioscience.com

